Agents Under Study

Ehsan Rahimy; Elham Rahimy; Anthony Joseph

doi:10.1201/9781003522577-5

Agents Under Study

Ehsan Rahimy, Elham Rahimy, Anthony Joseph

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The advent of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has undoubtedly revolutionized the field of ophthalmology and how physicians manage many potentially debilitating retinal conditions. In the recently published 5-year outcomes with anti-VEGF therapy from the Comparison of Age-Related Macular Degeneration Treatment Trials, a remarkable 50% of follow-up participants had visual acuity of 20/40 or better; however, 20% of individuals had acuity of 20/200 or worse. 1 While this represents a significant improvement over previous natural history studies prior to the commencement of the anti-VEGF era, it is a reminder that much work remains to be accomplished.

Original language	English (US)
Title of host publication	Anti-Vegf
Subtitle of host publication	Use in Ophthalmology
Publisher	CRC Press
Pages	29-46
Number of pages	18
ISBN (Electronic)	9781040140789
ISBN (Print)	9781630913212
DOIs	https://doi.org/10.1201/9781003522577-5
State	Published - Jan 1 2024
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1201/9781003522577-5

Cite this

@inbook{e77c576d27454f97a4dfd2ca39a7c2e9,

title = "Agents Under Study",

abstract = "The advent of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has undoubtedly revolutionized the field of ophthalmology and how physicians manage many potentially debilitating retinal conditions. In the recently published 5-year outcomes with anti-VEGF therapy from the Comparison of Age-Related Macular Degeneration Treatment Trials, a remarkable 50% of follow-up participants had visual acuity of 20/40 or better; however, 20% of individuals had acuity of 20/200 or worse. 1 While this represents a significant improvement over previous natural history studies prior to the commencement of the anti-VEGF era, it is a reminder that much work remains to be accomplished.",

author = "Ehsan Rahimy and Elham Rahimy and Anthony Joseph",

note = "Publisher Copyright: {\textcopyright} 2017 Taylor & Francis Group, LLC.",

year = "2024",

month = jan,

day = "1",

doi = "10.1201/9781003522577-5",

language = "English (US)",

isbn = "9781630913212",

pages = "29--46",

booktitle = "Anti-Vegf",

publisher = "CRC Press",

address = "United States",

}

TY - CHAP

T1 - Agents Under Study

AU - Rahimy, Ehsan

AU - Rahimy, Elham

AU - Joseph, Anthony

PY - 2024/1/1

Y1 - 2024/1/1

N2 - The advent of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has undoubtedly revolutionized the field of ophthalmology and how physicians manage many potentially debilitating retinal conditions. In the recently published 5-year outcomes with anti-VEGF therapy from the Comparison of Age-Related Macular Degeneration Treatment Trials, a remarkable 50% of follow-up participants had visual acuity of 20/40 or better; however, 20% of individuals had acuity of 20/200 or worse. 1 While this represents a significant improvement over previous natural history studies prior to the commencement of the anti-VEGF era, it is a reminder that much work remains to be accomplished.

AB - The advent of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has undoubtedly revolutionized the field of ophthalmology and how physicians manage many potentially debilitating retinal conditions. In the recently published 5-year outcomes with anti-VEGF therapy from the Comparison of Age-Related Macular Degeneration Treatment Trials, a remarkable 50% of follow-up participants had visual acuity of 20/40 or better; however, 20% of individuals had acuity of 20/200 or worse. 1 While this represents a significant improvement over previous natural history studies prior to the commencement of the anti-VEGF era, it is a reminder that much work remains to be accomplished.

UR - http://www.scopus.com/inward/record.url?scp=85201886485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85201886485&partnerID=8YFLogxK

U2 - 10.1201/9781003522577-5

DO - 10.1201/9781003522577-5

M3 - Chapter

AN - SCOPUS:85201886485

SN - 9781630913212

SP - 29

EP - 46

BT - Anti-Vegf

PB - CRC Press

ER -

Agents Under Study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this